Aimmune Therapeutics

YTD

ALL

Why Robinhood?

You can watch AIMT and buy or sell other stocks, ETFs, and their options commission-free!

About AIMT

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system.

CEO

Andrew Oxtoby, MBA

CEOAndrew Oxtoby, MBA

Employees

—

Employees—

Headquarters

Bridgewater, New Jersey

HeadquartersBridgewater, New Jersey

Founded

2011

Founded2011

Employees

—

Employees—

AIMT Key Statistics

Market cap

2.26B

Market cap2.26B

Price-Earnings ratio

-7.68

Price-Earnings ratio-7.68

Dividend yield

—

Dividend yield—

Average volume

1.45M

Average volume1.45M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$37.00

52 Week high$37.00

52 Week low

$10.09

52 Week low$10.09

People also own

Based on the portfolios of people who own AIMT. This list is generated using Robinhood data, and it’s not a recommendation.